Gemtuzumab Ozogamicin

[MAF] Gemtuzumab ozogamicin (Mylotarg) Concentrate For Infusion 5 mg

1. In combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they:
   • do not have acute promyelocytic leukaemia,
   • only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and
   • start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.

[MSHL] Gemtuzumab ozogamicin Powder For Concentrate For Solution For Infusion Vial 5 mg

1. In combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they:
   • do not have acute promyelocytic leukaemia,
   • only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and
   • start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

31/08/2022 Gemtuzumab ozogamicin for untreated de novo CD33-positive acute myeloid leukaemia

The Ministry of Health’s Drug Advisory Committee has recommended:

• Gemtuzumab ozogamicin 5 mg powder for concentrate for solution for infusion in combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they:

  • do not have acute promyelocytic leukaemia,

  • only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and

  • start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.

Funding status

[R] Gemtuzumab ozogamicin 5 mg powder for concentrate for solution for infusion is recommended for inclusion on the Cancer Drug List (Medication Assistance Fund and MediShield Life monthly claim limit of SG$3200) for the abovementioned indication from 1 September 2022.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration